Abstract:: The low solubility of an active pharmaceutical ingredient particularly biopharmaceutics classification system (BCS) Class II drugs leads to a lower dissolution profile, which in result causes a reduction in the overall bioavailability of drugs. Numerous approaches like nanotechnology, solid dispersion technique, micronization techniques, etc were aimed by scientists in the past to resolve this issue, but still not enough to get the desired outcomes. : Key focus of this review is the study of the advantages and disadvantages of cocrystallization, nanotechnology and solid dispersions drug delivery techniques and the benefits of using cocrystallization techniques over the above-mentioned techniques. : Various parameters including pharmaceutical, pharmacological and toxicological effects related to these mentioned drug delivery systems have been compared. Their advantages and disadvantages have been elaborated. : For drug delivery purpose, the cocrystallization process has numerous advantages over nanotechnology and solid dispersions drug delivery techniques discussed in the text. Cocrystallization is a newer technique that can modify the physicochemical and pharmaceutical properties of active pharmaceutical ingredients (API) with low solubility, low stability or sensitivity toward environmental hazards like temperature, moisture or photostability issues. During cocrystallization, the drug and the coformer interact with each other non-covalently in a fixed stoichiometric ratio. The availability of a large number of coformers makes this technique to be favorable for the researchers in designing cocrystals of newer and older API’s. : Although solid dispersions and nanotechnology techniques are being utilized to a larger extent, still there are some drawbacks of these techniques like stability, toxicological factors and protection from environmental factors that need to be considered, while the cocrystallization process drastically modifies the various pharmaceutical parameters without altering the pharmacological properties of API’s. Here in this review, we performed a comparative analysis between nanotechnology, solid dispersion and cocrystallization techniques along with the importance of cocrystallization in the modification of drug profile and various applications in the pharmaceutical and allied industry.

Comparative dissolution profiling of generic and standard drug under BCS Based Biowaiver conditions

Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development

COMPARISON OF GLOBAL REGULATORY GUIDELINES FOR AVAILABILITY OF DIFFERENT BIOWAIVER PROVISIONS AND APPLICATION REQUIREMENTS OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) BASED BIOWAIVER.

Dissolution profiles of BCS class II drugs generated by the gastrointestinal simulator alpha has an edge over the compendial USP II method

Justification of widened dissolution specifications of an extended-release product using physiologically based biopharmaceutics modeling

A Physiologically Based Pharmacokinetic Model for Studying the Biowaiver Risk of Biopharmaceutics Classification System Class I Drugs With Rapid Elimination: Dexketoprofen Trometamol Case Study

Introduction of WHO's Biowaiver Policy for Oral Generic Drugs

Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs

A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products

Biorelevant dissolution testing and physiologically based absorption modeling to predict in vivo performance of supersaturating drug delivery systems

Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets

Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium Sulfate

Analysis of Factors Related to Variation in Dissolution Profiles Estimated from Continuously Conducted Dissolution Tests of Generic Products

A Comparative Study of Selected Drug Delivery Systems: Key Emphasis on Cocrystallization

Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets

In–vitro Bioequivalence Study Between four Different Marketed Formulations of Gliclazide with Sustained Release Metformin Hydrochloride Tablet as an Anti-Diabetic Drug

COMPARISON BETWEEN GENERIC DRUGS AND BRAND NAME DRUGS FROM BIOEQUIVALENCE AND THERMOEQUIVALENCE PROSPECTIVE

Technical Requirements for Biopharmaceutics Classification System-Based Biowaiver in China

A comparative study on vildagliptin brand and its generic equivalents using dissolution test as quality control measure tool

Modeling and comparison of dissolution profiles for different brands of albendazole boluses